Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review.
Expert Rev Vaccines
; 15(7): 829-51, 2016 07.
Article
em En
| MEDLINE
| ID: mdl-26840060
ABSTRACT
BACKGROUND:
Hepatitis A and B are two of the most common vaccine-preventable diseases and vaccination for Hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for those at risk of contracting HAV and/or HBV through their occupation, travel or lifestyle.OBJECTIVE:
To describe the vaccine efficacy, immunogenicity, effectiveness and safety of the combined vaccine against hepatitis A and hepatitis B.METHODS:
A systematic review of the literature published between 1990 and 2015.RESULTS:
Anti-HAV seropositivity rates ranged from 96.2% to 100% and anti-HBs seroprotection rates from 82% to 100%. Antibodies persisted up to 15 years and geometric mean concentration (GMC) remained above the seropositivity cut-off value for both. Anti-HAV and anti-HBs immune responses were lower in less immunocompetent individuals one month after completion of the immunization schedule. The safety profiles of Twinrix(TM) and monovalent hepatitis A and B vaccines were similar.CONCLUSION:
The vaccine offers satisfactory long-term immunogenicity rates, expected duration of protection and safety profile similar to the monovalent hepatitis A or B vaccines.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
/
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Vacinas contra Hepatite B
/
Vacinas contra Hepatite A
/
Hepatite A
/
Hepatite B
Tipo de estudo:
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Expert Rev Vaccines
Ano de publicação:
2016
Tipo de documento:
Article